(CME) Going Flat Out for Glycemic Control: The Role of New Basal Insulins in Patient-Centered T2DM Management

This activity is supported by an educational grant from Sanofi US.


Click to Read the Supplement.

Based on material presented at the 2018 Metabolic & Endocrine Disease Summit (MEDS), this CME supplement to Clinician Reviews provides an overview of evidence and best practices for individualizing and intensifying antihyperglycemic therapy using current basal insulin options to achieve patient-centered goals in individuals with type 2 diabetes mellitus (T2DM). Physician assistants, nurse practitioners and nurses will have the opportunity to complete pre- and post-assessment questions to earn a maximum of 1.5 free CME/CE credits.

Dr. Vanita Aroda and Ms. Davida Kruger walk readers through the following learning objectives:

  • Explain the role/usage of ultralong-acting basal insulins for addressing the underlying pathophysiology of T2DM
  • Compare ultralong-acting and other basal insulins regarding therapeutic characteristics, including pharmacokinetic/pharmacodynamic profiles, efficacy, safety, and dosing
  • Develop patient-centered treatment regimens that include ultralong-acting insulins to minimize barriers to successful use of basal insulin therapy

Click to Read the Supplement.

Next Article: